-
1
-
-
0035932519
-
Cytokine pathways and joint inflammation in rheumatoid arthritis
-
Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907-916 (2001).
-
(2001)
N. Engl. J. Med.
, vol.344
, Issue.12
, pp. 907-916
-
-
Choy, E.H.1
Panayi, G.S.2
-
2
-
-
0023712236
-
Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
-
Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31(8), 1041-1045 (1988).
-
(1988)
Arthritis Rheum.
, vol.31
, Issue.8
, pp. 1041-1045
-
-
Saxne, T.1
Palladino Jr., M.A.2
Heinegard, D.3
Talal, N.4
Wollheim, F.A.5
-
3
-
-
0029085746
-
Cytokines in rheumatoid arthritis
-
Houssiau FA. Cytokines in rheumatoid arthritis. Clin. Rheumatol. 14(Suppl. 2). 10-13 (1995).
-
(1995)
Clin. Rheumatol.
, vol.14
, Issue.SUPPL. 2
, pp. 10-13
-
-
Houssiau, F.A.1
-
4
-
-
0012786007
-
Epidemiology
-
In: Management. Utsinger P, Zvaifler N, Ehrlich G (Ed.). JB Lippincott, Philadelphia, PA, USA
-
Mitchell D. Epidemiology. In: Rheumatoid Arthritis: Etiology, Diagnosis, Management. Utsinger P, Zvaifler N, Ehrlich G (Ed.). JB Lippincott, Philadelphia, PA, USA, 133-137 (1985).
-
(1985)
Rheumatoid Arthritis: Etiology, Diagnosis
, pp. 133-137
-
-
Mitchell, D.1
-
5
-
-
12444256001
-
Multidisciplinary ambulatory care for the elderly arthritis patient
-
In: Moskowitz H, Haug M (Eds). Springer, New York, USA
-
Robinson H. Multidisciplinary ambulatory care for the elderly arthritis patient. In: Arthritis and the Elderly. Moskowitz H, Haug M (Eds). Springer, New York, USA, 146-149 (1986).
-
(1986)
Arthritis and the Elderly
, pp. 146-149
-
-
Robinson, H.1
-
6
-
-
0038011833
-
Evolving concepts of rheumatoid arthritis
-
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 423(6937), 356-361 (2003).
-
(2003)
Nature
, vol.423
, Issue.6937
, pp. 356-361
-
-
Firestein, G.S.1
-
7
-
-
1442352158
-
Epidemiology and burden of illness of rheumatoid arthritis
-
Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 22(Suppl. 2), 1-12 (2004).
-
(2004)
Pharmacoeconomics
, vol.22
, Issue.SUPPL. 2
, pp. 1-12
-
-
Kvien, T.K.1
-
8
-
-
0018920615
-
The epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence, and mortality
-
Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am. J. Epidemiol. 111(1), 87-98 (1980).
-
(1980)
Am. J. Epidemiol.
, vol.111
, Issue.1
, pp. 87-98
-
-
Linos, A.1
Worthington, J.W.2
O'Fallon, W.M.3
Kurland, L.T.4
-
9
-
-
16844371735
-
Classification and epidemiology
-
In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Elsevier Science, Phildelphia, PA, USA
-
MacGregor AJ, Silman AJ. Classification and epidemiology. In: Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Elsevier Science, Phildelphia, PA, USA, 757-763 (2003).
-
(2003)
Rheumatology
, pp. 757-763
-
-
MacGregor, A.J.1
Silman, A.J.2
-
10
-
-
0031968825
-
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
-
Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41(5), 778-799 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
, Issue.5
, pp. 778-799
-
-
Lawrence, R.C.1
Helmick, C.G.2
Arnett, F.C.3
-
11
-
-
0023024826
-
Occurrence of rheumatoid arthritis in a nationwide series of twins
-
Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J. Rheumatol. 13(5), 899-902 (1986).
-
(1986)
J. Rheumatol.
, vol.13
, Issue.5
, pp. 899-902
-
-
Aho, K.1
Koskenvuo, M.2
Tuominen, J.3
Kaprio, J.4
-
12
-
-
0027375302
-
Twin concordance rates for rheumatoid arthritis: Results from a nationwide study
-
Silman AJ, MacGregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 32(10), 903-907 (1993).
-
(1993)
Br. J. Rheumatol.
, vol.32
, Issue.10
, pp. 903-907
-
-
Silman, A.J.1
MacGregor, A.J.2
Thomson, W.3
-
13
-
-
0032746370
-
Socio-economic consequences of rheumatoid arthritis in the first years of the disease
-
Albers JM, Kuper HH, Van Riel PL et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 38(5), 423-430 (1999).
-
(1999)
Rheumatology (Oxford)
, vol.38
, Issue.5
, pp. 423-430
-
-
Albers, J.M.1
Kuper, H.H.2
Van Riel, P.L.3
-
14
-
-
0034123823
-
Direct and indirect costs of rheumatoid arthritis to an employer
-
Birnbaum HG, Barton M, Greenberg PE et al. Direct and indirect costs of rheumatoid arthritis to an employer. J. Occup. Environ. Med. 42(6), 588-596 (2000).
-
(2000)
J. Occup. Environ. Med.
, vol.42
, Issue.6
, pp. 588-596
-
-
Birnbaum, H.G.1
Barton, M.2
Greenberg, P.E.3
-
15
-
-
0142135697
-
Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients
-
Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 48(10), 2750-2762 (2003).
-
(2003)
Arthritis Rheum.
, vol.48
, Issue.10
, pp. 2750-2762
-
-
Michaud, K.1
Messer, J.2
Choi, H.K.3
Wolfe, F.4
-
16
-
-
26944465819
-
Diagnosis and management of rheumatoid arthritis
-
Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am. Fam. Physician 72(6), 1037-1047 (2005).
-
(2005)
Am. Fam. Physician
, vol.72
, Issue.6
, pp. 1037-1047
-
-
Rindfleisch, J.A.1
Muller, D.2
-
17
-
-
0033001678
-
An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline
-
Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42(6), 1209-1218 (1999).
-
(1999)
Arthritis Rheum.
, vol.42
, Issue.6
, pp. 1209-1218
-
-
Yelin, E.1
Wanke, L.A.2
-
18
-
-
6744245548
-
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)
-
Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39(6), 603-611 (2000).
-
(2000)
Rheumatology (Oxford)
, vol.39
, Issue.6
, pp. 603-611
-
-
Young, A.1
Dixey, J.2
Cox, N.3
-
19
-
-
0036210887
-
Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS)
-
Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis. 61(4), 335-340 (2002).
-
(2002)
Ann. Rheum. Dis.
, vol.61
, Issue.4
, pp. 335-340
-
-
Young, A.1
Dixey, J.2
Kulinskaya, E.3
-
20
-
-
32544439865
-
The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits
-
Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J. Occup. Environ. Med. 48(2), 135-148 (2006).
-
(2006)
J. Occup. Environ. Med.
, vol.48
, Issue.2
, pp. 135-148
-
-
Ozminkowski, R.J.1
Burton, W.N.2
Goetzel, R.Z.3
Maclean, R.4
Wang, S.5
-
21
-
-
20244372077
-
Therapeutic strategies for rheumatoid arthritis
-
O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350(25), 2591-2602 (2004).
-
(2004)
N. Engl. J. Med.
, vol.350
, Issue.25
, pp. 2591-2602
-
-
O'Dell, J.R.1
-
22
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
-
(2006)
Arthritis Rheum.
, vol.54
, Issue.1
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
-
23
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
-
Klareskog L, van der Heijde DM, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
-
(2004)
Lancet
, vol.363
, Issue.9410
, pp. 675-681
-
-
Klareskog, L.1
van der Heijde, D.M.2
de Jager, J.P.3
-
24
-
-
8444239359
-
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
-
St Clair EW, van der Heijde DM, Smolen J et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.11
, pp. 3432-3443
-
-
St Clair, E.W.1
van der Heijde, D.M.2
Smolen, J.3
-
25
-
-
0034735827
-
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
-
Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000).
-
(2000)
N. Engl. J. Med.
, vol.343
, Issue.22
, pp. 1586-1593
-
-
Bathon, J.M.1
Martin, R.W.2
Fleischmann, R.M.3
-
26
-
-
27744514865
-
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
-
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.11
, pp. 3381-3390
-
-
Goekoop-Ruiterman, Y.P.1
de Vries-Bouwstra, J.K.2
Allaart, C.F.3
-
27
-
-
3242677099
-
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial
-
Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004).
-
(2004)
Lancet
, vol.364
, Issue.9430
, pp. 263-269
-
-
Grigor, C.1
Capell, H.2
Stirling, A.3
-
28
-
-
33748518459
-
Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis
-
(Abstract 207)
-
van der Heijde DM, Landewe R, Keystone E, Van Riel PL, Sasso E, Perez J. Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis. Arthritis Rheum. 52(Suppl. 9), (2005) (Abstract 207).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.SUPPL. 9
-
-
van der Heijde, D.M.1
Landewe, R.2
Keystone, E.3
Van Riel, P.L.4
Sasso, E.5
Perez, J.6
-
29
-
-
33748504851
-
Three years of sustained halting of radiographic progression with combination etanercept and methotrexate: Results from the TEMPO Trial
-
(Abstract)
-
van der Heijde DM, Klareskog L, Wajdula J, Pedersen R, Fatenejad S. Three years of sustained halting of radiographic progression with combination etanercept and methotrexate: results from the TEMPO Trial. Arthritis Rheum. 52(Suppl. 9), L10-L14 (2005) (Abstract).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.SUPPL. 9
-
-
van der Heijde, D.M.1
Klareskog, L.2
Wajdula, J.3
Pedersen, R.4
Fatenejad, S.5
-
30
-
-
0030068817
-
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria
-
van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, Van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39(1), 34-40 1996).
-
(1996)
Arthritis Rheum.
, vol.39
, Issue.1
, pp. 34-40
-
-
van Gestel, A.M.1
Prevoo, M.L.2
van't Hof, M.A.3
van Rijswijk, M.H.4
van de Putte, L.B.5
Van Riel, P.L.6
-
31
-
-
0031715621
-
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
-
van Gestel AM, Haagsma CJ, Van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41(10), 1845-1850 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
, Issue.10
, pp. 1845-1850
-
-
van Gestel, A.M.1
Haagsma, C.J.2
Van Riel, P.L.3
-
32
-
-
33646597828
-
Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - Results from the nationwide Danish "DANBIO" database
-
Ostergaard M, Unkerskov J, Krough NS et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - results from the nationwide Danish "DANBIO" database. Ann. Rheum. Dis. 64(Suppl. III), OP0011 (2005).
-
(2005)
Ann. Rheum. Dis.
, vol.64
, Issue.SUPPL. III
-
-
Ostergaard, M.1
Unkerskov, J.2
Krough, N.S.3
-
33
-
-
33344461104
-
Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study)
-
(Abstract 1839)
-
Cohen S, Greenwald M, Dougados M et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study). Arthritis Rheum. 52(Suppl. 9), (2005) (Abstract 1839).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.SUPPL. 9
-
-
Cohen, S.1
Greenwald, M.2
Dougados, M.3
-
34
-
-
24944498854
-
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
-
Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, Issue.11
, pp. 1114-1123
-
-
Genovese, M.C.1
Becker, J.C.2
Schiff, M.3
-
35
-
-
39549111980
-
Effectiveness of biologics and disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: Real-world outcomes from the RADIUS observational registry
-
(Abstract 1947)
-
Weaver A, Lautzenheiser RL, Schiff MH et al. Effectiveness of biologics and disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: real-world outcomes from the RADIUS observational registry. Arthritis Rheum. 52(Suppl. 9), (2005) (Abstract 1947).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.SUPPL. 9
-
-
Weaver, A.1
Lautzenheiser, R.L.2
Schiff, M.H.3
-
36
-
-
2342551979
-
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
-
Genovese MC, Cohen S, Moreland L et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50(5), 1412-1419 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.5
, pp. 1412-1419
-
-
Genovese, M.C.1
Cohen, S.2
Moreland, L.3
-
37
-
-
27444447691
-
Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDs: 1 year results of the ASSURE trial
-
[Op0012])
-
Weinblatt ME, Combe B, White A, Aranda R, Becker J, Keystone E. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDs: 1 year results of the ASSURE trial. Ann. Rheum. Dis. 64(Suppl. III [Op0012]), 60 (2005).
-
(2005)
Ann. Rheum. Dis.
, vol.64
, Issue.SUPPL. III
, pp. 60
-
-
Weinblatt, M.E.1
Combe, B.2
White, A.3
Aranda, R.4
Becker, J.5
Keystone, E.6
-
38
-
-
33645119818
-
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome
-
de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann. Rheum. Dis. 65(4), 524-542 (2005).
-
(2005)
Ann. Rheum. Dis.
, vol.65
, Issue.4
, pp. 524-542
-
-
de Koning, H.D.1
Bodar, E.J.2
Simon, A.3
van der Hilst, J.C.4
Netea, M.G.5
van der Meer, J.W.6
-
39
-
-
18644370644
-
Rapid responses to anakinra in patients with refractory adult-onset Still's disease
-
Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52(6), 1794-1803 (2005).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.6
, pp. 1794-1803
-
-
Fitzgerald, A.A.1
Leclercq, S.A.2
Yan, A.3
Homik, J.E.4
Dinarello, C.A.5
-
40
-
-
8444229328
-
Anakinra in mutation-negative NOMID/CINCA syndrome: Comment on the articles by Hawkins et al and Hoffman and Patel
-
Frenkel J, Wulffraat NM, Kuis W. Anakinra in mutation-negative NOMID/ CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum. 50(11), 3738-3739 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.11
, pp. 3738-3739
-
-
Frenkel, J.1
Wulffraat, N.M.2
Kuis, W.3
-
41
-
-
22144447157
-
The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide
-
Kallinich T, Hoffman HM, Roth J, Keitzer R. The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand. J. Rheumatol. 34(3), 246-249 (2005).
-
(2005)
Scand. J. Rheumatol.
, vol.34
, Issue.3
, pp. 246-249
-
-
Kallinich, T.1
Hoffman, H.M.2
Roth, J.3
Keitzer, R.4
-
42
-
-
0025274640
-
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
-
Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33(3), 305-315 (1990).
-
(1990)
Arthritis Rheum.
, vol.33
, Issue.3
, pp. 305-315
-
-
Arend, W.P.1
Dayer, J.M.2
-
43
-
-
18244425295
-
The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis
-
Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl. 2), ii3-ii10 (2003)
-
(2003)
Rheumatology (Oxford)
, vol.42
, Issue.SUPPL. 2
-
-
Dayer, J.M.1
-
44
-
-
0025304539
-
Rheumatoid arthritis. Pathophysiology and implications for therapy
-
Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322(18), 1277-1289 (1990).
-
(1990)
N. Engl. J. Med.
, vol.322
, Issue.18
, pp. 1277-1289
-
-
Harris Jr., E.D.1
-
46
-
-
0031786230
-
Treatment of rheumatoid arthritis with IL-1 inhibitors
-
Gabay C, Arend WP. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin. Immunopathol. 20(1-2), 229-246 (1998).
-
(1998)
Springer Semin. Immunopathol.
, vol.20
, Issue.1-2
, pp. 229-246
-
-
Gabay, C.1
Arend, W.P.2
-
47
-
-
0025255530
-
Quantitative analysis of cytokine gene expression in rheumatoid arthritis
-
Firestein GS, varo-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144(9), 3347-3353 (1990).
-
(1990)
J. Immunol.
, vol.144
, Issue.9
, pp. 3347-3353
-
-
Firestein, G.S.1
Varo-Gracia, J.M.2
Maki, R.3
-
48
-
-
0026802287
-
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair
-
Chu CQ Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 31(10), 653-661 (1992).
-
(1992)
Br. J. Rheumatol.
, vol.31
, Issue.10
, pp. 653-661
-
-
Chu, C.Q.1
Field, M.2
Allard, S.3
Abney, E.4
Feldmann, M.5
Maini, R.N.6
-
49
-
-
3442875303
-
Pathogenesis of bone and cartilage destruction in rheumatoid arthritis
-
Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl. 2), ii11-ii16 (2003).
-
(2003)
Rheumatology (Oxford)
, vol.42
, Issue.SUPPL. 2
-
-
Goldring, S.R.1
-
50
-
-
0029046142
-
Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and 1L-1 β by site-directed mutagenesis. Identification of a single site in IL-1Ra and two sites in IL-1 β
-
Evans RJ, Bray J, Childs JD et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and 1L-1 β by site-directed mutagenesis. Identification of a single site in IL-1Ra and two sites in IL-1 β. J. Biol. Chem. 270(19), 11477-11483 (1995).
-
(1995)
J. Biol. Chem.
, vol.270
, Issue.19
, pp. 11477-11483
-
-
Evans, R.J.1
Bray, J.2
Childs, J.D.3
-
51
-
-
0025713953
-
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
-
Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343(6256), 336-340 (1990).
-
(1990)
Nature
, vol.343
, Issue.6256
, pp. 336-340
-
-
Hannum, C.H.1
Wilcox, C.J.2
Arend, W.P.3
-
52
-
-
0023617050
-
A urine inhibitor of interleukin-1 activity that blocks ligand binding
-
Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J. Immunol. 139(5), 1546-1549 (1987).
-
(1987)
J. Immunol.
, vol.139
, Issue.5
, pp. 1546-1549
-
-
Seckinger, P.1
Lowenthal, J.W.2
Williamson, K.3
Dayer, J.M.4
MacDonald, H.R.5
-
53
-
-
0025021471
-
Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist
-
Eisenberg SP, Evans RJ, Arend WP et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343(6256), 341-346 (1990).
-
(1990)
Nature
, vol.343
, Issue.6256
, pp. 341-346
-
-
Eisenberg, S.P.1
Evans, R.J.2
Arend, W.P.3
-
54
-
-
34147139093
-
-
In: Thomson, Montvale, USA
-
Kineret. In: Physician's Desk Reference. Thomson, Montvale, USA, 594-596 (2006).
-
(2006)
Physician's Desk Reference
, pp. 594-596
-
-
Kineret1
-
55
-
-
0038434492
-
Pharmacokinetics of anakinra in subjects with different levels of renal function
-
Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin. Pharmacol. Ther. 74(1), 85-94 (2003).
-
(2003)
Clin. Pharmacol. Ther.
, vol.74
, Issue.1
, pp. 85-94
-
-
Yang, B.B.1
Baughman, S.2
Sullivan, J.T.3
-
56
-
-
17444394445
-
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
-
Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12), 2196-2204 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
, Issue.12
, pp. 2196-2204
-
-
Bresnihan, B.1
Alvaro-Gracia, J.M.2
Cobby, M.3
-
57
-
-
0036190776
-
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
-
Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(3), 614-624 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, Issue.3
, pp. 614-624
-
-
Cohen, S.1
Hurd, E.2
Cush, J.3
-
58
-
-
3442885115
-
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
-
Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63(9), 1062-1068 (2004).
-
(2004)
Ann. Rheum. Dis.
, vol.63
, Issue.9
, pp. 1062-1068
-
-
Cohen, S.B.1
Moreland, L.W.2
Cush, J.J.3
-
59
-
-
0037389680
-
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial
-
Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48(4), 927-934 (2003).
-
(2003)
Arthritis Rheum.
, vol.48
, Issue.4
, pp. 927-934
-
-
Fleischmann, R.M.1
Schechtman, J.2
Bennett, R.3
-
60
-
-
0018882143
-
Measurement of patient outcome in arthritis
-
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 23(2), 137-145 (1980)
-
(1980)
Arthritis Rheum.
, vol.23
, Issue.2
, pp. 137-145
-
-
Fries, J.F.1
Spitz, P.2
Kraines, R.G.3
Holman, H.R.4
-
61
-
-
0029044362
-
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
-
Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6), 727-735 (1995).
-
(1995)
Arthritis Rheum.
, vol.38
, Issue.6
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
-
62
-
-
0027412974
-
Minimum important difference between patients with rheumatoid arthritis: The patient's perspective
-
Wells GA, Tugwell P, Kraag GR et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J. Rheumatol. 20, 557-560 (1993).
-
(1993)
J. Rheumatol.
, vol.20
, pp. 557-560
-
-
Wells, G.A.1
Tugwell, P.2
Kraag, G.R.3
-
63
-
-
0017658738
-
Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films
-
Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol. Diagn. (Stockh.) 18(4), 481-491 (1977).
-
(1977)
Acta Radiol. Diagn. (Stockh.)
, vol.18
, Issue.4
, pp. 481-491
-
-
Larsen, A.1
Dale, K.2
Eek, M.3
-
64
-
-
0034083128
-
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic. progression and correlation of Genant and Larsen scores
-
Jiang Y, Genant H, Watt I, Cobby M, Bresnihan B, Aitchison R. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000).
-
(2000)
Arthritis Rheum.
, vol.43
, pp. 1001-1009
-
-
Jiang, Y.1
Genant, H.2
Watt, I.3
Cobby, M.4
Bresnihan, B.5
Aitchison, R.6
-
65
-
-
0036845130
-
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist).in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial
-
Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist).in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(11), 2838-2846 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, Issue.11
, pp. 2838-2846
-
-
Nuki, G.1
Bresnihan, B.2
Bear, M.B.3
McCabe, D.4
-
66
-
-
0042867068
-
Anakinra (Kineret®) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis
-
(Abstract)
-
Shergy W, Cohen S, Greenwald M et al. Anakinra (Kineret®) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Arthritis Rheum. 46(Suppl. 9), LB 10 (2002) (Abstract).
-
(2002)
Arthritis Rheum.
, vol.46
, Issue.SUPPL. 9
-
-
Shergy, W.1
Cohen, S.2
Greenwald, M.3
-
67
-
-
0037309790
-
Interleukin-1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis
-
Cohen SB, Woolley JM, Chan W. interleukin-1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. 30(2), 225-231 (2003).
-
(2003)
J. Rheumatol.
, vol.30
, Issue.2
, pp. 225-231
-
-
Cohen, S.B.1
Woolley, J.M.2
Chan, W.3
-
68
-
-
3442877556
-
Combination of TNFα soluble receptors (sR) with IL-1 and IL-17 sR is more effective to reduce in vitro inflammation response of synoviocytes stimulated with RA PBMC supernatants
-
(Abstract 127)
-
Chevrel G, Garnero P, Mirosses P. Combination of TNFα soluble receptors (sR) with IL-1 and IL-17 sR is more effective to reduce in vitro inflammation response of synoviocytes stimulated with RA PBMC supernatants. Arthritis Rheum. 43(Suppl. 9) (2000) (Abstract 127).
-
(2000)
Arthritis Rheum.
, vol.43
, Issue.SUPPL. 9
-
-
Chevrel, G.1
Garnero, P.2
Mirosses, P.3
-
69
-
-
3442892397
-
Combination therapy with anakinra and PEGylated soluble tumor necrosis factor type I (Pegsunercept).in rheumatoid arthritis (RA): Preliminary analysis of clinical, functional, synovial tissue and radiographic outcomes from a phase II, open-label, mode of action study
-
(Abstract 211)
-
Rooney T, Madigan A, Greenan L et al. Combination therapy with anakinra and PEGylated soluble tumor necrosis factor type I (Pegsunercept).in rheumatoid arthritis (RA): preliminary analysis of clinical, functional, synovial tissue and radiographic outcomes from a phase II, open-label, mode of action study. Arthritis Rheum. 48(Suppl. 9) (2003) (Abstract 211).
-
(2003)
Arthritis Rheum.
, vol.48
, Issue.SUPPL. 9
-
-
Rooney, T.1
Madigan, A.2
Greenan, L.3
-
71
-
-
5044223401
-
Effective use of the recombinant intereukin-1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis
-
Verbsky JW, White AJ. Effective use of the recombinant intereukin-1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31(10), 2071-2075 (2004).
-
(2004)
J. Rheumatol.
, vol.31
, Issue.10
, pp. 2071-2075
-
-
Verbsky, J.W.1
White, A.J.2
-
72
-
-
18644385243
-
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
-
Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201(9), 1479-1486 (2005).
-
(2005)
J. Exp. Med.
, vol.201
, Issue.9
, pp. 1479-1486
-
-
Pascual, V.1
Allantaz, F.2
Arce, E.3
Punaro, M.4
Banchereau, J.5
-
73
-
-
0036899758
-
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases
-
Aksentijevich I, Nowak M, Mallah M et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46(12),3340-3348 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, Issue.12
, pp. 3340-3348
-
-
Aksentijevich, I.1
Nowak, M.2
Mallah, M.3
-
74
-
-
0010464874
-
PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing
-
Wang L, Manji GA, Grenier JM et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing. J. Biol. Chem. 277(33), 29874-29880 (2002).
-
(2002)
J. Biol. Chem.
, vol.277
, Issue.33
, pp. 29874-29880
-
-
Wang, L.1
Manji, G.A.2
Grenier, J.M.3
-
75
-
-
17244381937
-
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease
-
Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52(4), 1283-1286 (2005).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.4
, pp. 1283-1286
-
-
Lovell, D.J.1
Bowyer, S.L.2
Solinger, A.M.3
-
76
-
-
21244481363
-
Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome
-
Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 44(5), 689-690 (2005).
-
(2005)
Rheumatology (Oxford)
, vol.44
, Issue.5
, pp. 689-690
-
-
Granel, B.1
Serratrice, J.2
Disdier, P.3
Weiller, P.J.4
-
77
-
-
4043104941
-
Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease
-
Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 50(8), 2708-2709 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.8
, pp. 2708-2709
-
-
Hawkins, P.N.1
Bybee, A.2
Aganna, E.3
McDermott, M.F.4
-
78
-
-
1042290321
-
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra
-
Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50(2), 607-612 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.2
, pp. 607-612
-
-
Hawkins, P.N.1
Lachmann, H.J.2
Aganna, E.3
McDermott, M.F.4
-
79
-
-
4344643654
-
IL-1RA in refractory systemic lupus erythematosus
-
Moosig F, Zeuner R, Renk C, Schroder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus 13(8), 605-606 (2004).
-
(2004)
Lupus
, vol.13
, Issue.8
, pp. 605-606
-
-
Moosig, F.1
Zeuner, R.2
Renk, C.3
Schroder, J.O.4
-
80
-
-
16344374294
-
Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis
-
Ostendorf B, Iking-Konert C, Kutz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64(4), 630-633 (2005).
-
(2005)
Ann. Rheum. Dis.
, vol.64
, Issue.4
, pp. 630-633
-
-
Ostendorf, B.1
Iking-Konert, C.2
Kutz, K.3
Jung, G.4
Sander, O.5
Schneider, M.6
-
81
-
-
4344699365
-
Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study
-
Tan AL, Matzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann. Rheum. Dis. 63(9), 1041-1045 (2004).
-
(2004)
Ann. Rheum. Dis.
, vol.63
, Issue.9
, pp. 1041-1045
-
-
Tan, A.L.1
Matzo-Ortega, H.2
O'Connor, P.3
Fraser, A.4
Emery, P.5
McGonagle, D.6
-
82
-
-
0028579768
-
A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index
-
Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J. Rheumatol. 21(12), 2281-2285 (1994).
-
(1994)
J. Rheumatol.
, vol.21
, Issue.12
, pp. 2281-2285
-
-
Calin, A.1
Garrett, S.2
Whitelock, H.3
-
83
-
-
0028575453
-
A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
-
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 21(12), 2286-2291 (1994).
-
(1994)
J. Rheumatol.
, vol.21
, Issue.12
, pp. 2286-2291
-
-
Garrett, S.1
Jenkinson, T.2
Kennedy, L.G.3
Whitelock, H.4
Gaisford, P.5
Calin, A.6
-
84
-
-
13244279795
-
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
-
Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. 64(2), 296-298 (2005).
-
(2005)
Ann. Rheum. Dis.
, vol.64
, Issue.2
, pp. 296-298
-
-
Haibel, H.1
Rudwaleit, M.2
Listing, J.3
Sieper, J.4
-
85
-
-
0028129277
-
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index
-
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J. Rheumatol. 21(9), 1694-1698 (1994).
-
(1994)
J. Rheumatol.
, vol.21
, Issue.9
, pp. 1694-1698
-
-
Jenkinson, T.R.1
Mallorie, P.A.2
Whitelock, H.C.3
Kennedy, L.G.4
Garrett, S.L.5
Calin, A.6
-
86
-
-
0034888069
-
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
-
Anderson JJ, Baron G, Van Der HD, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 44(8), 1876-1886 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
, Issue.8
, pp. 1876-1886
-
-
Anderson, J.J.1
Baron, G.2
Van Der, H.D.3
Felson, D.T.4
Dougados, M.5
-
87
-
-
2642550601
-
Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial
-
Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol. 31(6), 1103-1111 (2004).
-
(2004)
J. Rheumatol.
, vol.31
, Issue.6
, pp. 1103-1111
-
-
Bresnihan, B.1
Newmark, R.2
Robbins, S.3
Genant, H.K.4
-
88
-
-
2642576804
-
The safety of anakinra in high-risk patients with active rheumatoid arthritis: Six-month observations of patients with comorbid conditions
-
Schiff MH, DiVittorio G, Tesser J et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 50(6), 1752-1760 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.6
, pp. 1752-1760
-
-
Schiff, M.H.1
DiVittorio, G.2
Tesser, J.3
-
89
-
-
1842425913
-
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis
-
Tesser J, Fleischmann R, Dore R et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis. J. Rheumatol. 31(4), 649-654 (2004).
-
(2004)
J. Rheumatol.
, vol.31
, Issue.4
, pp. 649-654
-
-
Tesser, J.1
Fleischmann, R.2
Dore, R.3
-
90
-
-
33746578466
-
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
-
(Epub ahead of print)
-
Fleischmann RM, Tesser J, Schiff M et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) (Epub ahead of print).
-
(2006)
Ann. Rheum. Dis.
-
-
Fleischmann, R.M.1
Tesser, J.2
Schiff, M.3
-
91
-
-
33748508698
-
Surveillance, Epidemiology, and End Results (SEER)
-
National Cancer Institute. Program Public-Use Data (1973-1999). [11 Registries, 1992-1999]. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission 2002
-
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Program Public-Use Data (1973-1999).[11 Registries, 1992-1999]. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission 2002 (2006).
-
(2006)
-
-
-
92
-
-
1542313935
-
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade
-
Buch MH, Bingham SJ, Seto Y et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum. 50(3), 725-728 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.3
, pp. 725-728
-
-
Buch, M.H.1
Bingham, S.J.2
Seto, Y.3
-
93
-
-
4444268519
-
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: Comment on the article by Buch et al
-
Saxne T, Larsson L, Geborek P. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al. Arthritis Rheum. 50(9), 3049-3050 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.9
, pp. 3049-3050
-
-
Saxne, T.1
Larsson, L.2
Geborek, P.3
-
94
-
-
33645890587
-
The use of anakinra in juvenile arthritis
-
Reiff A. The use of anakinra in juvenile arthritis. Curr. Rheumatol. Rep. 7(6), 434-440 (2005).
-
(2005)
Curr. Rheumatol. Rep.
, vol.7
, Issue.6
, pp. 434-440
-
-
Reiff, A.1
-
95
-
-
0030960980
-
Preliminary definition of improvement in juvenile arthritis
-
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 40(7), 1202-1209 (1997).
-
(1997)
Arthritis Rheum.
, vol.40
, Issue.7
, pp. 1202-1209
-
-
Giannini, E.H.1
Ruperto, N.2
Ravelli, A.3
Lovell, D.J.4
Felson, D.T.5
Martini, A.6
-
96
-
-
0036735247
-
Examining the efficacy of biologic therapy: Are there real differences?
-
Fleischmann RM. Examining the efficacy of biologic therapy: are there real differences? J. Rheumatol. 65, 27-32 (2002).
-
(2002)
J. Rheumatol.
, vol.65
, pp. 27-32
-
-
Fleischmann, R.M.1
|